SOPHIE is brought to you by Innovation Factory

Adapsyn Bioscience enters into strategic collaboration with Evotec

ORIGINAL PRESS RELEASE, PR Newswire, September 21, 2022

Adapsyn Bioscience Inc., a chemical bioinformatics company that discovers novel drug-like small molecules, today announced a strategic collaboration with Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO). Under the collaboration, Evotec will have the opportunity to evaluate small molecules developed by Adapsyn as potential therapeutic candidates in proprietary and partnered drug discovery projects.

The Adapsyn platform uses artificial intelligence and machine learning to identify and isolate novel drug-like metabolites from microbes for downstream assay and development. Evotec has extensive biochemical, cellular, and phenotypic screening capabilities, and particular expertise in natural product drug discovery and development. The multi-year collaboration will provide Evotec with libraries of bioactive small molecules to screen against high value targets of interest to Evotec and its partners. Adapsyn will be responsible for library generation and compound production efforts.



Share this article